相关实验视频

Updated: Jan 12, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

研究NETO2在口腔状细胞癌中的表达,预后价值和对免疫微环境的调节作用

Jinhang Wang¹, Zifeng Cui², Kaicheng Yang²

¹Department of Stomatology, The Second Hospital of Shijiazhuang, No. 53, Huaxi Road, Shijiazhuang, Hebei, 050000, China.

|November 5, 2025

概括

NETO2基因过度表达预测口腔状细胞癌 (OSCC) 的存活率较低. 高的NETO2与免疫细胞透和潜在的免疫疗法反应相关,这表明它是治疗点.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫学免疫学免疫学

背景情况:

在口腔状细胞癌 (OSCC) 中NETO2基因的预后意义尚未得到充分确立.
这项研究旨在阐明在OSCC中NETO2表达模式和临床相关性.

研究的目的:

研究OSCC组织中的NETO2表达水平.
确定NETO2表达和患者预后 (总生存率和无进展生存率) 之间的关联.
探索NETO2与瘤免疫微环境之间的关系,包括免疫细胞透和免疫疗法反应潜力.

主要方法:

在公共OSCC数据集 (TCGA,GEO) 中分析NETO2表达.
卡普兰-梅尔生存分析和诺莫格拉姆开发用于预后预测.
单细胞RNA测序 (scRNA-seq) 用于识别表达NETO2和相关途径的细胞类型.
评估NETO2与瘤突变负担,免疫微环境和药物敏感性的相关性.
实验验证NETO2在OSCC细胞入侵,增殖和迁移中的功能作用.

主要成果:

在OSCC中,NETO2显著过度表达,高表达与较差的OS和PFS有关.
一个开发出来的名图表显示了对患者生存的良好预测准确性.
scRNA-seq确定了T细胞群中的NETO2表达和与免疫信号通路的关联.
较高的NETO2表达与增加的免疫细胞透,潜在的免疫疗法反应和差异性药物敏感性相关.
实验证实了NETO2在促进OSCC细胞入侵,增殖和迁移方面的作用.

结论:

在OSCC中,NETO2作为一个重要的预后生物标志物.
NETO2表达通过免疫微环境的调节影响瘤的进展.
针对NETO2为OSCC提供了一个潜在的治疗策略.

关键词:

免疫微环境是一个微环境.在NETO2中,使用的是NETO2.口腔状细胞癌的癌症.预测生物标志物预测生物标志物这就是ScRNA-seqq.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...